# Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus

> **NCT02388997** · PHASE2 · COMPLETED · sponsor: **University of Virginia** · enrollment: 31 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** omalizumab
- **BIOLOGICAL:** Rhinovirus (strain 16)

## Key facts

- **NCT ID:** NCT02388997
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-01
- **Primary completion:** 2017-05-04
- **Final completion:** 2017-05-04
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2018-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02388997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02388997, "Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02388997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*